ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 564

Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis

Corina Mogosan1, Luminita Enache1, Denisa Stanciu1, Daniela Opris2, Simona Rednic3, Magda Parvu4, Horatiu Popoviciu5, Ruxandra Ionescu2 and Catalin Codreanu1, 1Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 2University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 3Rheumatology, Emergency County Clinical Hospital Cluj Napoca, Cluj-Napoca, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, 5Rheumatology, Emergency County Hospital, Targu Mures, Romania

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANA, Biologics and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Therapeutic target in rheumatoid arthritis (RA) aims at achieving remission or low disease activity. Among the known poor prognostic factors are anti–citrullinated protein antibody (ACPA) and rheumatoid factor (RF). Clinical significance and therapeutic implications of the positivity of antinuclear antibodies (ANA) in serum of RA patients before starting the biological treatment is still under debate.

Purpose: The implications of ANA positivity, as a prognostic factor, in the therapeutic response to biologic therapy in RA, as measured by DAS28 score.

Methods: observational study; all data were gathered from the electronic database of Romanian Registry of Rheumatic Diseases (RRBR) which comprises all RA patients following biological treatment in the country. There were included only RA patients who were evaluated for the presence of ANA, before initiating any biologic therapy.

Results: 740 RA patients were included in the study, mean age 56.50 years (± 12.59), 84.5% women, mean disease duration 12.54 years (± 7.67). At baseline (prior to any biologic start), 26.9% patients were positive for ANA, 89.8% for RF, 37% for ACPA, 35.1% were double seropositive ( for RF and ACPA) while 13.1% were triple seropositive (RF, ACPA, and ANA) and the mean DAS28 was 5.09 ± 2.35. 72.4% patients were treated with TNF-alpha blockers, while 27.6% with anti-CD20 drugs. During evolution, 22% of subjects required switch of therapy. Biologics persistency (the duration of therapy under one drug) was 31.70 (± 29.95) months and the latest DAS 28 score was 2.90 ± 1.41. There were statistically significant differences between DAS28 values at all assessments, depending on the presence of ANA. At biological start, DAS28 score in ANA positive group was 5.70 ± 2.06, while in ANA negative group was 4.86 ± 2.41 (p <0.001). Concerning efficacy, assessed by the latest DAS28, ANA positive group had a score of 3.32 ± 1.61, compared to 2.74 ± 1.30 in ANA negative patients (p <0.001). The drug persistence in ANA positive patients was 22.65 ± 25.68 months, versus 34.86 ± 30.71 months in ANA negative group (p <0.001). For patients who required switch of therapy, DAS28 score at switch time was 5.42 ± 1.52 in ANA positive group, versus 4.79 ± 1.80 in ANA negative group (p = 0.05). There is a poor positive association between ANA positivity and DAS28 at all assessments (r = 0.2, p <0.01) and ACPA positivity (r = 0.2, p <0.01) and a negative correlation between ANA positivity and drug persistence (r = – 0.2, p <0.01). Linear regression showed that the best predictor of the current value of DAS28 is ANA positivity, independent of the presence of RF, ACPA, double or triple seropositivity (t=2, p<0.05).

Conclusion: ANA positivity in patients with RA, before starting any biological therapy, may be a poor prognostic factor for the therapeutic efficacy, as well as for the drug persistence. More studies are needed to confirm these observations.


Disclosure: C. Mogosan, None; L. Enache, None; D. Stanciu, None; D. Opris, AbbVie, UCB, MSD, Teva, 5,UCB, MSD, Eli Lilly, Pfizer, Roche, Sanofi, Teva, BMS, 8; S. Rednic, None; M. Parvu, None; H. Popoviciu, None; R. Ionescu, None; C. Codreanu, None.

To cite this abstract in AMA style:

Mogosan C, Enache L, Stanciu D, Opris D, Rednic S, Parvu M, Popoviciu H, Ionescu R, Codreanu C. Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/value-of-antinuclear-antibodies-as-a-predictor-of-therapeutic-efficacy-of-biologics-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-antinuclear-antibodies-as-a-predictor-of-therapeutic-efficacy-of-biologics-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology